Lehtinen M, Dillner J, Knekt P, Luostarinen T, Aromaa A, Kirnbauer R, Koskela P, Paavonen J, Peto R, Schiller J T, Hakama M
National Public Health Institute, Helsinki, Finland.
BMJ. 1996 Mar 2;312(7030):537-9. doi: 10.1136/bmj.312.7030.537.
To study human papillomavirus type 16 in the aetiology of cervical carcinoma.
Within a cohort of 18814 Finnish women followed up to 23 years a nested case-control study was conducted based on serological diagnosis of past infection with human papillomavirus type 16.
72 women (27 with invasive carcinoma and 45 with in situ carcinoma) and 143 matched controls were identified during the follow up.
Relative risk of cervical carcinoma in presence of IgG antibodies to human papillomavirus type 16.
After adjustment for smoking and for antibodies to various other agents of sexually transmitted disease, such as herpes simplex virus type 2 and Chlamydia trachomatis, the only significant association was with infection with human papillomavirus type 16 (odds ratio 12.5; 95% confidence interval 2.7 to 57, 2P<0.001).
This prospective study provides epidemiological evidence that infection with human papillomavirus type 16 confers an excess risk for subsequent development of cervical carcinoma.
研究16型人乳头瘤病毒在宫颈癌病因学中的作用。
在对18814名芬兰女性长达23年的随访队列中，基于对既往16型人乳头瘤病毒感染的血清学诊断进行了一项巢式病例对照研究。
随访期间确定了72名女性（27例浸润癌患者和45例原位癌患者）以及143名匹配对照。
存在16型人乳头瘤病毒IgG抗体时患宫颈癌的相对风险。
在对吸烟以及针对其他各种性传播疾病病原体（如2型单纯疱疹病毒和沙眼衣原体）的抗体进行校正后，唯一显著的关联是与16型人乳头瘤病毒感染有关（比值比12.5；95%置信区间2.7至57，P<0.001）。
这项前瞻性研究提供了流行病学证据，表明16型人乳头瘤病毒感染会增加后续患宫颈癌的风险。
